Neuralink has successfully implanted its N1 brain-computer interface (BCI) chip in multiple human patients, moving the technology from laboratory proof-of-concept to real-world clinical validation. The first implant occurred on January 28, 2024, when Noland Arbaugh, a 29-year-old quadriplegic patient, received the device as part of the company's PRIME Study. Within days of surgery, Arbaugh was able to control a computer cursor using only his thoughts, demonstrating that the technology works reliably in living patients outside controlled lab environments.

How Does the Neuralink N1 Chip Actually Work?

The N1 chip is built around a high-density electrode array designed to capture electrical signals directly from the brain. The device contains 1,024 electrodes distributed across 64 ultra-fine, flexible threads that are surgically implanted into the motor cortex, the brain region responsible for movement control. These threads are thinner than human hair, allowing surgeons to place them with precision while minimizing damage to surrounding brain tissue.

Once implanted, the electrodes detect neural activity and send wireless signals to an external receiver. A decoding algorithm then translates these brain signals into digital commands, allowing users to control computers or mobile devices through thought alone. This wireless architecture means patients don't need a physical cable running through their skin, reducing infection risk and improving quality of life compared to earlier BCI designs.

What Clinical Milestones Has Neuralink Achieved So Far?

The company's progress has accelerated significantly since its first human implant. By 2026, Neuralink has moved well beyond initial feasibility studies and is now gathering critical long-term stability data. A second patient received an implant in 2024, and the engineering team made successful enhancements to electrode thread insertion techniques to improve long-term reliability. These refinements are essential because the device must function reliably for years, not just weeks or months.

The regulatory pathway has also cleared important hurdles. The FDA granted Neuralink a Breakthrough Device Designation in 2023, which accelerates the approval process for devices that address unmet medical needs. This designation reflects the agency's recognition that BCIs could restore function to paralyzed patients in ways no other treatment can.

What Are the Key Technical Specifications?

• Electrode Count: The N1 chip contains 1,024 electrodes, providing dense neural signal coverage across the implant site for precise movement detection and control.
• Thread Design: 64 individual threads deliver the electrodes to the brain, with each thread thin enough to minimize tissue damage during insertion and long-term implantation.
• Wireless Communication: The device transmits neural data wirelessly to external receivers, eliminating the need for percutaneous cables that could become infected or damaged.
• Signal Processing: Internal algorithms decode neural impulses in real time, translating brain activity into digital commands with sufficient speed and accuracy for practical device control.

How Does Neuralink Compare to Other Brain-Computer Interface Companies?

Neuralink is not alone in the race to commercialize BCIs. Synchron, a competing neurotechnology company, implanted its Stentrode device in a US patient in July 2022, actually predating Neuralink's first human implant by more than a year. However, Neuralink's approach using a fully implanted microchip with thousands of electrodes differs from Stentrode's less invasive design, which threads a device through blood vessels rather than directly into brain tissue.

Both approaches have trade-offs. Stentrode's minimally invasive method reduces surgical risk but may capture fewer neural signals. Neuralink's direct implantation offers higher signal fidelity and more precise control, but requires more extensive neurosurgery. The field is still young enough that multiple technical approaches may coexist, serving different patient populations and clinical needs.

When Will Neuralink Devices Be Available to the General Public?

As of June 2026, the Neuralink N1 remains in clinical trial phase and is not available for commercial purchase. The company has not yet announced official pricing for the procedure, though the cost will likely be substantial given the surgical expertise required and the custom nature of the implant. Broad commercial availability will depend on completing long-term safety and efficacy data, obtaining full FDA approval, and establishing manufacturing and surgical infrastructure across multiple medical centers.

The timeline for these milestones remains uncertain. Regulatory approval for novel medical devices typically takes years, and BCIs are among the most complex devices the FDA has ever reviewed. However, the Breakthrough Device Designation suggests the agency is committed to moving the approval process forward faster than it would for a standard medical device.

What Does This Mean for Paralyzed Patients and the Future of Neurotechnology?

For patients with severe paralysis, BCIs represent a genuine restoration of independence. Noland Arbaugh's ability to control a cursor within days of implantation showed that the technology can work immediately, not just in theory. As Neuralink and competitors gather more data, the focus is shifting from basic cursor control to more complex motor functions and digital interactions. Future applications could include controlling robotic limbs, restoring communication in locked-in patients, or even treating neurological conditions like Parkinson's disease or epilepsy.

The broader significance lies in proving that direct brain-to-machine communication is feasible and safe in humans. This validation opens the door to decades of refinement, from improving electrode design to developing better decoding algorithms. As the field matures, costs will likely decrease and accessibility will improve, though it will remain a specialized procedure for patients with severe neurological conditions for the foreseeable future.